Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)Young Kwang Chae, Francis J. Giles, Ayush Arya et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 468
Sebaceous carcinoma: evidence-based clinical practice guidelinesJoshua L. Owen, Michael K. Wong, Nour Kibbi et al.|The Lancet Oncology|2019Cited by 204
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana R. Halle, Veronica Rotemberg, Allison Betof Warner et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 64